{"id":546468,"date":"2021-06-07T16:44:02","date_gmt":"2021-06-07T16:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=546468"},"modified":"2021-06-07T16:44:02","modified_gmt":"2021-06-07T16:44:02","slug":"traumatic-brain-injury-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-hope-biosciences-pinteon-therapeutics-sanbio-neurovive-pharmaceutical-cellvation-and-many-othe","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/traumatic-brain-injury-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-hope-biosciences-pinteon-therapeutics-sanbio-neurovive-pharmaceutical-cellvation-and-many-othe_546468.html","title":{"rendered":"Traumatic brain injury Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Hope Biosciences, Pinteon Therapeutics, SanBio, NeuroVive Pharmaceutical, Cellvation and Many Othe"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1623041521.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Traumatic brain injury Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Hope Biosciences, Pinteon Therapeutics, SanBio, NeuroVive Pharmaceutical, Cellvation and Many Othe\" src=\"https:\/\/www.abnewswire.com\/uploads\/1623041521.jpeg\" alt=\"Traumatic brain injury Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Hope Biosciences, Pinteon Therapeutics, SanBio, NeuroVive Pharmaceutical, Cellvation and Many Othe\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Traumatic brain injury Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Traumatic brain injury (TBI), <\/strong>a form of acquired brain injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object pierces the skull and enters brain tissue.&nbsp; Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A person with a mild TBI may remain conscious or may experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/traumatic-brain-injury-tbi-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Traumatic brain injuries Pipeline<\/a><\/strong><strong> Insight, 2021<\/strong>&rdquo; report provides comprehensive insights about <strong>20+ companies and 20+ pipeline drugs<\/strong> in Traumatic brain injuries pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/traumatic-brain-injury-tbi-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/traumatic-brain-injury-tbi-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <\/strong><strong>Traumatic brain injury Companies<\/strong><strong> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Vasopharm GmbH<\/li>\n<li>SanBio, Inc.<\/li>\n<li>Avid Radiopharmaceuticals<\/li>\n<li>Hope Biosciences<\/li>\n<li>Pinteon Therapeutics<\/li>\n<li>SanBio<\/li>\n<li>NeuroVive Pharmaceutical<\/li>\n<li>Cellvation<\/li>\n<li>NoNO Inc.<\/li>\n<li>Avanir Pharmaceuticals<\/li>\n<li>Hibernaid, Inc.<\/li>\n<li>Tetra Therapeutics<\/li>\n<li>CytoDyn<\/li>\n<li>Annovis Bio<\/li>\n<li>Abliva<\/li>\n<li>Therapeutic solutions<\/li>\n<li>Nyrada<\/li>\n<li>Ischemix<\/li>\n<li>Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/traumatic-brain-injury-tbi-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/traumatic-brain-injury-tbi-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s <\/strong><strong>Traumatic brain injury report<\/strong><strong> covers around 50+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase II and Phase II\/III)<\/li>\n<li>Mid-stage products (Phase II and Phase II\/III)<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/traumatic-brain-injury-tbi-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Traumatic brain injury Key Products<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>VAS203<\/li>\n<li>SB623<\/li>\n<li>Flortaucipir F18<\/li>\n<li>PNT001<\/li>\n<li>HB-adMSCs<\/li>\n<li>NeuroSTAT<\/li>\n<li>CEVA101<\/li>\n<li>TRPM7 Antagonist<\/li>\n<li>AVP-786<\/li>\n<li>BPN14770<\/li>\n<li>Leronlimab<\/li>\n<li>R-phenserine<\/li>\n<li>Mesenchymal stem cells<\/li>\n<li>Ciclosporin intravenous<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/traumatic-brain-injury-tbi-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/traumatic-brain-injury-tbi-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current <\/strong>&nbsp;<strong>Traumatic brain injury<\/strong> <strong>Treatment<\/strong><strong> Scenario and<\/strong><strong> Traumatic brain injury Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Traumatic brain injury drugs?<\/li>\n<li>How many Traumatic brain injury drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Traumatic brain injury?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the &nbsp;Traumatic brain injury therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Traumatic brain injury and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: https:\/\/www.delveinsight.com\/sample-request\/traumatic-brain-injury-tbi-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<br \/> Executive Summary<br \/> Traumatic brain injuries: Overview<br \/> Pipeline Therapeutics<br \/> &bull; Comparative Analysis<br \/> Therapeutic Assessment<br \/> Traumatic brain injuries &ndash; DelveInsight&rsquo;s Analytical Perspective<br \/> In-depth Commercial Assessment<br \/> &bull; Traumatic brain injuries companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<br \/> Traumatic brain injuries Collaboration Deals<br \/> Late Stage Products (Phase III) <br \/> &bull; Comparative Analysis<br \/> VAS203: Vasopharm<br \/> Drug profiles in the detailed report&hellip;..<br \/> Mid Stage Products (Phase II) <br \/> &bull; Comparative Analysis<br \/> SB263: SanBio<br \/> Drug profiles in the detailed report&hellip;..<br \/> Early stage products (Phase I\/II)<br \/> &bull; Comparative Analysis<br \/> HB-adMSCs: Hope Biosciences<br \/> Drug profiles in the detailed report&hellip;..<br \/> Inactive Products<br \/> &bull; Comparative Analysis<br \/> Traumatic brain injuries Key Companies<br \/> Traumatic brain injuries Key Products<br \/> Traumatic brain injuries- Unmet Needs<br \/> Traumatic brain injuries- Market Drivers and Barriers<br \/> Traumatic brain injuries- Future Perspectives and Conclusion<br \/> Traumatic brain injuries Analyst Views<br \/> Traumatic brain injuries Key Companies<br \/> Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=traumatic-brain-injury-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-hope-biosciences-pinteon-therapeutics-sanbio-neurovive-pharmaceutical-cellvation-and-many-othe\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/traumatic-brain-injury-tbi-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/traumatic-brain-injury-tbi-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/traumatic-brain-injury-tbi-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=traumatic-brain-injury-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-hope-biosciences-pinteon-therapeutics-sanbio-neurovive-pharmaceutical-cellvation-and-many-othe\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Traumatic brain injury Pipeline Traumatic brain injury (TBI), a form of acquired brain injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/traumatic-brain-injury-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-hope-biosciences-pinteon-therapeutics-sanbio-neurovive-pharmaceutical-cellvation-and-many-othe_546468.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-546468","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=546468"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546468\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=546468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=546468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=546468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}